Concepedia

Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events

Jun Ishihara, Kazuto Fukunaga, Ako Ishihara, Hans M. Larsson, Lambert Potin, Peyman Hosseinchi, Gabriele Galliverti, Melody A. Swartz, Jeffrey A. Hubbell

Science Translational Medicine · 2017 · 156 citations · 36 references

DOIFull text

Open access

Concepts

Abstract

T cells, resulting in a delay of distant tumor growth as well. This simple and translatable approach of engineered ECM-binding Abs may present a viable and safer approach in checkpoint blockade.

References

36

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

F. Stephen Hodi, Steven O’Day, David F. McDermott et al. · New England Journal of Medicine · 2010 · 15.2K citations · Full text

, , +12

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

James Larkin, Vanna Chiarion‐Sileni, René González et al. · New England Journal of Medicine · 2015 · 8.1K citations · Full text

, , +17

Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

Gordon J. Freeman, Andrew J. Long, Yoshiko Iwai et al. · The Journal of Experimental Medicine · 2000 · 5.2K citations · Full text

, , +17

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

Yoshiko Iwai, Masayoshi Ishida, Yoshimasa Tanaka et al. · Proceedings of the National Academy of Sciences · 2002 · 3.2K citations

, , +17

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

Stefani Spranger, Riyue Bao, Thomas F. Gajewski · Nature · 2015 · 2.8K citations

, , +10